Opinion of the Transparency Council – peginterferon alfa-2a
At its meeting on 14 April 2025, the Transparency Council adopted opinion No. 64/2025 on the inclusion of medicinal products containing the active substance peginterferon alfa-2a in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. C.79.a. (C92.1 chronic myeloid leukemia)